J
Jacquelyn W. Zimmerman
Researcher at Johns Hopkins University
Publications - 35
Citations - 571
Jacquelyn W. Zimmerman is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 9, co-authored 23 publications receiving 379 citations. Previous affiliations of Jacquelyn W. Zimmerman include University of Alabama at Birmingham & Johns Hopkins University School of Medicine.
Papers
More filters
Journal ArticleDOI
Cancer cell proliferation is inhibited by specific modulation frequencies.
Jacquelyn W. Zimmerman,Michael J. Pennison,Ivan A. Brezovich,Nengjun Yi,Celeste T. Yang,Ryne C. Ramaker,Devin Absher,Richard M. Myers,Niels Kuster,Filomena Costa,Alexandre Barbault,Boris Pasche +11 more
TL;DR: These findings uncover a novel mechanism controlling the growth of cancer cells at specific modulation frequencies without affecting normal tissues, which may have broad implications in oncology.
Journal ArticleDOI
Treatment of advanced hepatocellular carcinoma with very low levels of amplitude-modulated electromagnetic fields.
Filomena Costa,A.H.C. de Oliveira,R. Meirelles,Marcel Cerqueira César Machado,T Zanesco,Rodrigo C. Surjan,M.C. Chammas,M de Souza Rocha,Desiree E. Morgan,Alan B. Cantor,Jacquelyn W. Zimmerman,Ivan A. Brezovich,Niels Kuster,Alexandre Barbault,Boris Pasche +14 more
TL;DR: Treatment with intrabuccally administered amplitude-modulated electromagnetic fields is safe, well tolerated, and shows evidence of antitumour effects in patients with advanced HCC.
Journal ArticleDOI
Targeted treatment of cancer with radiofrequency electromagnetic fields amplitude-modulated at tumor-specific frequencies.
Jacquelyn W. Zimmerman,Hugo Jimenez,Michael J. Pennison,Ivan A. Brezovich,Desiree E. Morgan,Albert Mudry,Frederico Costa,Alexandre Barbault,Boris Pasche +8 more
TL;DR: Intrabuccal administration of 27.12 MHz radiofrequency electromagnetic fields (EMF), which are amplitude-modulated at tumor-specific frequencies, results in long-term objective responses in patients with cancer and is not associated with any significant adverse effects.
Journal ArticleDOI
Patient-derived Organoid Pharmacotyping is a Clinically Tractable Strategy for Precision Medicine in Pancreatic Cancer.
Toni T. Seppälä,Jacquelyn W. Zimmerman,Elisabetta Sereni,Dennis Plenker,Reecha Suri,Noah Rozich,Alex B. Blair,Dwayne L. Thomas,Jonathan Teinor,Ammar A. Javed,Hardik Patel,John L. Cameron,William R. Burns,Jin He,David A. Tuveson,Elizabeth M. Jaffee,James R. Eshleman,Annamaria Szabolcs,David P. Ryan,David T. Ting,Christopher L. Wolfgang,Richard A. Burkhart +21 more
TL;DR: Rapid development of PDOs from patients undergoing surgery for PDAC is eminently feasible within the perioperative recovery period, enabling the potential for pharmacotyping to guide postoperative adjuvant chemotherapeutic selection.
Journal ArticleDOI
Molecular mechanisms of Polyphyllin I-induced apoptosis and reversal of the epithelial-mesenchymal transition in human osteosarcoma cells.
Junli Chang,Wang Hongshen,Xianyang Wang,Yongjian Zhao,Dongfeng Zhao,Wang Chenglong,Yimian Li,Zhi-Lie Yang,Sheng Lu,Qinghua Zeng,Jacquelyn W. Zimmerman,Qi Shi,Yongjun Wang,Yanping Yang +13 more
TL;DR: Insight is provided into the mechanism underlying the anticancer activity of PPI in human osteosarcoma cells and the molecular targets involved.